CD317 profiling distinguishes bone marrow stromal cell subtypes with distinct functional impact upon T cell proliferation and polarisation

Research output: Contribution to journalMeeting abstractpeer-review


Purpose: The development of enhanced therapeutic interventions
using human mesenchymal stromal cells (MSCs) for regenerative
medicine is a priority in osteoarthritis research. MSCs are a heterogeneous
cell population with immunomodulatory and anti-inflammatory
properties. We have identified a novel biomarker (CD317) that allows
the isolation of MSCs subpopulations with tissue regenerative properties
(Y201, CD317-) and non-differentiating MSCs with an enriched proinflammatory
transcriptional profile (Y202, CD317þ) that make up an
average of 9% of the total MSCs population. We investigated the
immunomodulatory function of these subpopulations to understand
their role in disease processes and potential impact on regenerative
Original languageEnglish
Article number556
Pages (from-to)S296-S297
Number of pages2
JournalOsteoarthritis and cartilage
Issue numberSupplement 1
Publication statusPublished - Apr 2018

Cite this